Skip to main content

The DNA damage response and breast cancer

Objective

We will exploit the DNA damage response (DDR) to assess and predict individual susceptibility and response focussed on breast cancer and breast cancer therapies. The 1st targeted therapy based on the DDR is inhibition of PARP by olaparib, which induces synthetic lethality in cancer cells with a specific DDR defect. Our members discovered olaparib, which is currently in Phase II trials. Its use in DDR deficient cancers represents a truly personalised healthcare approach. Due to the complexity of the DDR more therapeutically exploitable cases of synthetic lethality are to be discovered, which may be applied to specific tumours and patients. To this end our objectives include: To determine key differences in the DDR between cancer and normal cells, because they constitute important targets for directed individual therapy; establish the roles of DDR mechanisms as these relate to damage induced by anti-cancer therapies to explain inter-individual variation in therapy response; define how different DDR pathways compensate for one another, because this may suggest how targeting one DDR component with a drug could have marked cytotoxic effects on a cancer but not on normal cells; develop and validate markers for functionality of the DDR in fresh tumour biopsies, directly from the clinic, for selection of patients for personalised treatment.
Collectively, this consortium has an unrivalled depth and breadth of expertise. We have access to a wide range of new and emerging technologies, while we bring complementary strengths to the project with regard to topics, models, materials, techniques and clinical links, which include the two largest cancer hospitals in Denmark and the Netherlands. Thus, the consortium represents the ‘state-of-the-art’ and has the scope to evolve their knowledge of the DDR into new and exciting areas for assessment of individual susceptibility and prediction of individual responses to cancer therapies, as well as development of new anti-cancer therapies

Call for proposal

FP7-HEALTH-2010-two-stage
See other projects for this call

Coordinator

ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM
Address
Dr Molewaterplein 40
3015 GD Rotterdam
Netherlands
Activity type
Higher or Secondary Education Establishments
EU contribution
€ 2 292 900
Administrative Contact
Rini De Crom (Dr.)

Participants (5)

THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE
United Kingdom
EU contribution
€ 685 867
Address
Trinity Lane The Old Schools
CB2 1TN Cambridge
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Keith Cann (Mr.)
KRAEFTENS BEKAEMPELSE
Denmark
EU contribution
€ 824 750
Address
Strandboulevarden 49
2100 Koebenhavn
Activity type
Research Organisations
Administrative Contact
Doris Vejby-Soerensen (Ms.)
ASTRAZENECA UK LIMITED
United Kingdom
EU contribution
€ 685 866
Address
1 Francis Crick Avenue Cambridge Biomedical Campus
CB2 0AA Cambridge
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Emma Barton (Dr.)
ACADEMISCH ZIEKENHUIS LEIDEN
Netherlands
EU contribution
€ 824 750
Address
Albinusdreef 2
2333 ZA Leiden
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Liesbeth Dorama (Ms.)
THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL
United Kingdom
EU contribution
€ 685 867
Address
Old Brompton Road 123
SW7 3RP London
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Binoo Rastogi (Ms.)